The Glucagon‐Like Peptide‐1 Receptor Agonist, Semaglutide, for the Treatment of Nonalcoholic Steatohepatitis

HepatologyVolume 74, Issue 4 p. 2290-2292 Hepatology Elsewhere The Glucagon-Like Peptide-1 Receptor Agonist, Semaglutide, for the Treatment of Nonalcoholic Steatohepatitis Laura E. Dichtel M.D., M.H.S., Laura E. Dichtel M.D., M.H.S. Neuroendocrine Unit, Division of Endocrinology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MASearch for more papers by this author Laura E. Dichtel M.D., M.H.S., Laura E. Dichtel M.D., M.H.S. Neuroendocrine Unit, Division of Endocrinology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MASearch for more papers by this author First published: 06 May 2021 https://doi.org/10.1002/hep.31886 Dr. Dichtel is supported by NIH K23 DK113220. Potential conflict of interest: Dr. Dichtel has received drug donation from Pfizer and scan analysis donation from Perspectum Diagnostics, both by investigator-initiated request. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article. Volume74, Issue4October 2021Pages 2290-2292 RelatedInformation